相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment
Giovanni Targher et al.
DIABETES & METABOLISM (2021)
Lipoprotein(a): Knowns, unknowns and uncertainties
Massimiliano Ruscica et al.
PHARMACOLOGICAL RESEARCH (2021)
New Insights Into the Regulation of Lipoprotein Metabolism by PCSK9: Lessons From Stable Isotope Tracer Studies in Human Subjects
Qidi Ying et al.
FRONTIERS IN PHYSIOLOGY (2021)
The KLB rs17618244 gene variant is associated with fibrosing MAFLD by promoting hepatic stellate cell activation
Nadia Panera et al.
EBIOMEDICINE (2021)
Proprotein Convertase Subtilisin/Kexin Type 9 A View beyond the Canonical Cholesterol-Lowering Impact
Chiara Macchi et al.
AMERICAN JOURNAL OF PATHOLOGY (2021)
The impact of race and ethnicity on lipoprotein(a) levels and cardiovascular risk
Gissette Reyes-Soffer
CURRENT OPINION IN LIPIDOLOGY (2021)
Low lipoprotein(a) levels and risk of disease in a large, contemporary, general population study
Anne Langsted et al.
EUROPEAN HEART JOURNAL (2021)
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)
Francois Mach et al.
EUROPEAN HEART JOURNAL (2020)
VLDL (Very-Low-Density Lipoprotein)-Apo E (Apolipoprotein E) May Influence Lp(a) (Lipoprotein [a]) Synthesis or Assembly
Mikael Croyal et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2020)
Liver transcriptomics highlights interleukin-32 as novel NAFLD-related cytokine and candidate biomarker
Guido Alessandro Baselli et al.
GUT (2020)
Mboat7 down-regulation by hyper-insulinemia induces fat accumulation in hepatocytes
Marica Meroni et al.
EBIOMEDICINE (2020)
Advanced fibrosis of non-alcoholic steatohepatitis affects the significance of lipoprotein(a) as a cardiovascular risk factor
Kanako Konishi et al.
ATHEROSCLEROSIS (2020)
MBOAT7 down-regulation by genetic and environmental factors predisposes to MAFLD
Marica Meroni et al.
EBIOMEDICINE (2020)
Lipoprotein(a) Lowering-From Lipoprotein Apheresis to Antisense Oligonucleotide Approach
Maria Francesca Greco et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Serum lipoprotein(a) levels and insulin resistance have opposite effects on fatty liver disease
Inha Jung et al.
ATHEROSCLEROSIS (2020)
Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association
Don P. Wilson et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2019)
Lipoprotein(a)-Lowering by 50 mg/dL (105 nmol/L) May Be Needed to Reduce Cardiovascular Disease 20% in Secondary Prevention
Christian M. Madsen et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2019)
Lipoprotein(a) Concentration and Risks of Cardiovascular Disease and Diabetes
Daniel F. Gudbjartsson et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Association of apolipoprotein E gene polymorphisms with blood lipids and their interaction with dietary factors
Israa M. Shatwan et al.
LIPIDS IN HEALTH AND DISEASE (2018)
Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study
Stephen Zewinger et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Association between lipoprotein(a) and nonalcoholic fatty liver disease among Korean adults
Ji Sun Nam et al.
CLINICA CHIMICA ACTA (2016)
The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent
Rosellina Margherita Mancina et al.
GASTROENTEROLOGY (2016)
Global Epidemiology of Nonalcoholic Fatty Liver Disease-Meta-Analytic Assessment of Prevalence, Incidence, and Outcomes
Zobair M. Younossi et al.
HEPATOLOGY (2016)
Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD
Fernando Bril et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis
Giovanni Targher et al.
JOURNAL OF HEPATOLOGY (2016)
Genetics of nonalcoholic fatty liver disease
Paola Dongiovanni et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2016)
Transmembrane 6 Superfamily Member 2 Gene Variant Disentangles Nonalcoholic Steatohepatitis From Cardiovascular Disease
Paola Dongiovanni et al.
HEPATOLOGY (2015)
Association of Nonalcoholic Fatty Liver Disease (NAFLD) with Hepatocellular Carcinoma (HCC) in the United States From 2004 to 2009
Zobair M. Younossi et al.
HEPATOLOGY (2015)
Statin use and non-alcoholic steatohepatitis in at risk individuals
Paola Dongiovanni et al.
JOURNAL OF HEPATOLOGY (2015)
Genetic Predisposition in NAFLD and NASH: Impact on Severity of Liver Disease and Response to Treatment
Paola Dongiovanni et al.
CURRENT PHARMACEUTICAL DESIGN (2013)
Lipoprotein(a): resurrected by genetics
F. Kronenberg et al.
JOURNAL OF INTERNAL MEDICINE (2013)
Lipoprotein(a) as a cardiovascular risk factor: current status
Borge G. Nordestgaard et al.
EUROPEAN HEART JOURNAL (2010)
Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease
P. Dongiovanni et al.
GUT (2010)
Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction
Pia R. Kamstrup et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Design and validation of a histological scoring system for nonalcoholic fatty liver disease
DE Kleiner et al.
HEPATOLOGY (2005)
Nonalcoholic fatty liver disease - A feature of the metabolic syndrome
G Marchesini et al.
DIABETES (2001)
分享论文
